EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 479 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma April 29, 2021 EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with... July 17, 2024 No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in... September 26, 2024 Load more HOT NEWS Cancer Research UK thanks Tania Bryer for a decade of fundraising... FDA Approves Durvalumab for Muscle Invasive Bladder Cancer Touching a nerve: How neuroscience could advance our understanding of cancer Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours
